Anthem Blue Cross Blue Shield

Lake Street has reiterated its Buy rating and $24 price target on BioTelemetry, Inc. (NASDAQ: BEAT), saying that the Anthem Blue Cross Blue Shield covering Mobile Cardiac Telemetry (MCT) is a positive for the company. Anthem Blue Cross Blue Shield now covers MCT for its roughly 36 million...